In an interview with Medtech Insight, Angelo De Rosa, the general manager of Boston Scientific’s cardiac rhythm management and electrophysiology businesses in Europe, Middle East and Africa (EMEA), discussed some of his company’s recent achievements and the opportunities it is addressing in 2022.

Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.

The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.

During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.